MANUAL

AlphaLISA® Human IL-3 Detection Kit

Product number: AL3134HV/C/F

Research Use Only. Not for use in diagnostic procedures.

Product Information

Application: This kit is designed for the quantitative determination of human human IL-3 in culture medias, cell lysates, cell supernatents and serum samples using a homogeneous AlphaLISA assay (no wash steps). The kit is using glycosylated human IL-3 as an analyte.

Specifications described below are based on assay performed in AlphaLISA Immunoassay Buffer 1X.

Sensitivity: Lower Detection Limit (LDL): 4.6 pg/mL

Lower Limit of Quantification (LLOQ): 15.9 pg/mL

EC_{50}: 76 ng/mL

Dynamic range: 4.6 – 300 000 pg/mL



Figure 1. Typical sensitivity curve in AlphaLISA Immunoassay Buffer. The data was generated using a white Optiplate™-384 microplate and the EnVision® Multilabel Plate Reader 2102 with Alpha option.

Storage: Store kit in the dark at +4°C.

Stability: This kit is stable for at least 6 months from the manufacturing date when stored in its original packaging and the recommended storage conditions.

Analyte of Interest

Human IL-3 is a 152 amino acid protein with significant glycosylation in vivo. It is secreted by activated T-cells after response to infection or inflammation and act as a growth factor for T-cells and members of the myeloid cell linage. It is also a key mediator for survival of hematopoietic cell progenitor stem cells. It acts by binding to a high affinity receptor, IL3R.

The human IL-3 AlphaLISA detection kit allows for the detection of human IL-3 in cell lysates and supernatants, along with serum and plasma. The kit as designed recognizes the glycosylated form of IL-3

Description of the AlphaLISA Assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm (Figure 2).



Figure 2. AlphaLISA Assay Principle.

Precautions

- The Alpha Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.
- Take precautionary measures to avoid contamination of the reagent solutions.
- The Biotinylated Anti-Analyte Antibody contains sodium azide. Contact with skin or inhalation should be avoided.

Kit Content: Reagents and Materials

Kit components	AL3134HV (100 assay points)**	AL3134C (500 assay points)	AL3134F (5000 assay points)
AlphaLISA Anti-IL-3 Acceptor beads stored in PBS, 0.05% Kathon CG/ICP, pH 7.2	20 µL @ 5 mg/mL (1 brown tube, white cap)	50 µL @ 5 mg/mL (1 brown tube, white cap)	500 µL @ 5 mg/mL (1 brown tube, white cap)
Streptavidin (SA)-coated Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon CG/ICP, pH 7.4	40 µL @ 5 mg/mL (1 brown tube, black cap)	100 µL @ 5 mg/mL (1 brown tube, black cap)	1 000 µL @ 5 mg/mL (1 brown tube, black cap)
Biotinylated Anti-IL-3 Antibody stored in PBS, 0.1% Tween-20, 0.05% NaN_3, pH 7.4	20 µL @ 500 nM (1 tube, black cap)	50 µL @ 500 nM (1 tube, black cap)	500 µL @ 500 nM (1 tube, black cap)
Lyophilized Glycosylated IL-3 from HEK293 cells ***	1 µg (1 tube, clear cap)	1 µg (1 tube, clear cap)	1 µg (1 tube, clear cap)
AlphaLISA Immunoassay Buffer (10X) *	2 mL, 1 small bottle	10 mL, 1 medium bottle	100 mL, 1 large bottle

* Extra buffer can be ordered separately (cat # AL000C: 10 mL, cat # AL000F: 100 mL).

** The number of assay points is based on an assay volume of 100 µL in 96-well plates or 50 µL in 96- or 384-well assay plates using the kit components at the recommended concentrations.

*** Reconstitute lyophilized analyte in 100 µL Milli-Q® grade H_2O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped 0.5 mL polypropylene vials and stored at -20°C for future experiments. The aliquoted analyte stored at -20°C is stable up to 30 days. The reconstituted material can tolerate up to two freeze-thaw cycles. However, freeze-thaw cycles should be avoided if possible. One vial contains an amount of analyte sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL3134S).

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001 % final in the assay) might decrease the AlphaLISA signal. Note that sodium azide from the Biotinylated Antibody stock solution will not interfere with the AlphaLISA signal (0.0001% final in the assay).

Specific additional required reagents and materials:

The following materials are recommended:

Item	Suggested source	Catalog #
TopSeal™-A Plus Adhesive Sealing Film	Revvity Inc.	6050185
EnVision®-Alpha Reader	Revvity Inc.	-

Recommendations

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000g, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q® grade H_2O (18 MΩ•cm) to dilute 10X AlphaLISA Immunoassay Buffer.
- When diluting the standard or samples, change tips between each standard or sample dilution. When loading reagents in the assay microplate, change tips between each standard or sample addition and after each set of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A Plus Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the TopSeal-A Plus Film.
- The AlphaLISA signal is detected with an EnVision Multilabel Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment.

Assay Procedure

IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The manual described below is an example for generating one standard curve in a 50 µL final assay volume (48 wells, triplicate determinations). The manuals also include testing samples in 452 wells. If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly, as shown in the table below. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.

- The standard dilution manual is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.

- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.

Format	# of data points	Volume				Plate recommendation
		Final	Sample	AlphaLISA Acceptor beads and Biotinylated Antibody	SA-Donor beads	
AL3134 HV	100	100 µL	10 µL	10 µL	80 µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
AL3134C	250	100 µL	10 µL	10 µL	80 µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
	500	50 µL	5 µL	5 µL	40 µL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate™-384 (cat # 6005350)
	1 250	20 µL	2 µL	2 µL	16 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate™-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	2 500	10 µL	1 µL	1 µL	8 µL	Light gray AlphaPlate-1536 (cat # 6004350)
AL3134F	5 000	50 µL	5 µL	5 µL	40 µL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate-384 (cat # 6005350)
	12 500	20 µL	2 µL	2 µL	16µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	25 000	10 µL	1 µL	1 µL	8 µL	Light gray AlphaPlate-1536 (cat # 6004350)

2 Step Manual described below is for 500 assay points including one standard curve (48 wells) and samples (452 wells). *If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.*

1) Preparation of 1X AlphaLISA Immunoassay Buffer:
   a. Add 5 mL of 10X AlphaLISA Immunoassay Buffer to 45 mL Milli-Q grade water.

2) Preparation of 1X AlphaLISA Lysis Buffer:
   a. Add 1 mL of 5X AlphaLISA Lysis Buffer to 5 mL of Milli-Q grade water.

3) Preparation human IL-3 analyte standard dilutions:

a. Reconstitute analyte by adding 100 µL of Milli-Q grade water to one tube of analyte to generate a 10 µg/mL solution.

b. Prepare standard dilutions as follows in 1X AlphaLISA Immunoassay Buffer

Tube	**Vol. of human IL-3 (µL)**	**Vol. of diluent (µL) ***	**[human IL-3] in standard curve**	
			(g/mL in 5 µL)	**(pg/mL in 5 µL)**
A	10 µL of human IL-3 stock	90	1.00E-06	1 000 000
B	60 µL of tube A	140	3.00E-07	300 000
C	60 µL of tube B	120	1.00E-07	100 000
D	60 µL of tube C	140	3.00E-08	30 000
E	60 µL of tube D	120	1.00E-08	10 000
F	60 µL of tube E	140	3.00E-09	3 000
G	60 µL of tube F	120	1.00E-09	1 000
H	60 µL of tube G	140	3.00E-10	300
I	60 µL of tube H	120	1.00E-10	100
J	60 µL of tube I	140	3.00E-11	30
K	60 µL of tube J	120	1.00E-11	10
L	60 µL of tube K	140	3.00E-12	3
M ** (background)	0	100	0	0
N ** (background)	0	100	0	0
O ** (background)	0	100	0	0
P ** (background)	0	100	0	0

* Dilute standards in diluent (e.g. 1X AlphaLISA Immunoassay Buffer).
At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.

** Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).

4) Preparation of 10X MIX AlphaLISA Anti-IL-3 Antibody Acceptor beads (100 µg/mL) + Biotinylated Anti-IL-3 Antibody (10 nM):

a. Prepare just before use.

b. Add 5 µL of 5 mg/mL AlphaLISA Anti-IL-3 Antibody Acceptor Bead and 5 µL of 500 nM Biotinylated Anti-IL-3 Antibody to 240 µL of 1X AlphaLISA Immunoassay Buffer.

5) Preparation of 1.25X Streptavidin (SA) Donor beads (25 µg/mL):

a. Prepare just before use.

b. Keep the beads under subdued laboratory lighting.

c. Add 10 µL of 5 mg/mL SA-Donor beads to 1990 µL of 1X AlphaLISA Immunoassay Buffer.

6) In a white Optiplate (384 wells):



Data Analysis

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a $1/Y^2$ data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3 x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Assay Performance Characteristics

AlphaLISA assay performance described below was determined using the 2 step manual using AlphaLISA Immunoassay Buffer (IAB).

- Assay Sensitivity:

The LDL was calculated as described above. The values correspond to the lowest concentration of analyte that can be detected in a volume of 5 µL using the recommended assay conditions.

LDL (pg/mL)	Buffer *	# of experiments
4.6	IAB	7
1.8	AlphaLISA Lysis Buffer (ALB)	7
10.8	DMEM + 10% FBS	7
29.4	RPMI + 10% FBS	7
11.6	FBS	7
1.7	RPMI + 10% FBS: AlphaLISA Lysis Buffer 1:1 dilution	7

* The standard was prepared in these diluents and all other components were diluted in IAB. Note that LDL can be decreased (i.e. sensitivity increased) by increasing the volume of analyte in the assay (e.g. use 10 µL of analyte in a final assay volume of 50 µL).

Performing assays in RPMI 1640 will see interference from the media. However, diluting samples in RPMI 1:1 with lysis buffer does restore the sensitivity of the kit.

- Assay Precision:

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in IAB, AlphaLISA Lysis Buffer, DMEM, RPMI or RPMI: AlphaLISA Lysis Buffer 1:1. Cell culture media was supplemented with 10% FBS. All other components were prepared in IAB. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well format.

- Intra-assay precision:

The intra-assay precision was determined by averaging 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

human IL-3	IAB	Lysis Buffer	DMEM + 10% FBS	RPMI + 10% FBS	FBS	RPMI:Lysis Buffer 1:1
CV (%)	4.2	1.9	2.2	2.8	1.9	5.9

- Inter-assay precision:

The inter-assay precision was determined comparing 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

human IL-3	IAB	Lysis Buffer	DMEM + 10% FBS	RPMI + 10% FBS	FBS	RPMI:Lysis Buffer 1:1
CV (%)	3.7	9.4	10	10	9.2	9.4

- Spike Recovery:

Known concentrations of analyte were spiked into IAB, DMEM + 10% FBS, RPMI +10% FBS, 100% FBS or RPMI + 10% FBS: Lysis buffer 1:1. All samples, including non-spiked buffer were measured in the assay. Note that the standard curves were prepared in the matrices used for the samples. All other components were diluted in IAB.

Spiked human IL-3 (ng/mL)	% Recovery					
	IAB	Lysis Buffer	DMEM + 10% FBS	RPMI + 10% FBS	FBS	RPMI:Lysis Buffer 1:1
10	110	116	103	89	87	97
3	104	108	105	110	94	126
1	98	89	102	94	91	121

Cell lysates Experiments

To validate the assay kit, Stimulated Jurkat cells were used. The standard curve should be performed in AlphaLISA Lysis Buffer.

Jurkat cells were grown in RPMI 1640 + 10% FBS to confluence and then plated into wells of a 96 well culture plate with the following amounts:

40 000; 20 000; 10 000; 5 000; 2 500; 1 250; 625; 313; 157; 79; 39 and 0 cells in RPMI + 10% FBS. Cells were treated as the following:

- One group was left untreated
- One group received 20 ng/mL of phorbol myristate acetate (PMA)
- One group received 2 ug/mL of phycohemagglutinin (PHA)
- One group received both.

The cells were left overnight.

The plate was centrifuged for 5 minutes at 1500 g, and the supernatant was carefully taken out and deposited in wells of a 96 well polypropylene plate. Each well received an equivalent volume of AlphaLISA Lysis buffer 1X.

To the cell pellet was added 100 uL of AlphaLISA Lysis buffer 1X and the plate was incubated for 30 minutes at 37ºC.

The lysate was tested against a standard curve of analyte in Lysis Buffer.



Signal can be observed starting at 2 500 cells per well. The signal is maximal where cells are treated with both PMA and PHA, as reported by Ryan, Lopez, Milton and Bardy (1991) Blood 77(6) pp 1195-1202.

Extrapolation on the standard curve show that the expression of IL-3 is linear to the number of cells present.



Cell supernatant Experiments

The cell supernatants collected above were also tested using a standard curve of human IL-3 diluted in RPMI 1640 + 10% FBS: AlphaLISA Lysis buffer 1:1.



Cells also show maximum expression when treated with both PMA and PHA. Extrapolations of the results for treated cells on the standard curve also show linear expression.



Human Serum and Plasma Experiments

Human serum and plasma from health donors were diluted 1:1 with AlphaLISA lysis buffer. Dilutions of 1:1, 1:2, 1:4, 1:8, 1:16 1:32 were performed with FBS:AlphaLISA Lysis buffer 1:1. A standard curve was also created using the manual described above using FBS:AlphaLISA Lysis buffer 1:1 as the diluent.

Results obtained for the serum and plasma dilutions were plotted on the standard curve.



All results were multiplied by two to account for the dilution in AlphaLISA Lysis buffer. Also, to note is that raw serum or plasma gave very high background, non-linear with the other dilutions. As such, a 1:1 dilution of serum or plasma samples is recommended.

Specificity Experiments

Cross-reactivity of the human IL-3 kit was tested using the following proteins up to 1 µg/mL in IAB.

Protein	% Cross-reactivity
Recombinant IL-3 from E.coli	104
Mouse IL-3	0.3

Troubleshooting Guide

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at: www.revvity.com

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, “Revvity”) do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product’s suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

www.revvity.com

revvity

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright ©2023, Revvity, Inc. All rights reserved.